相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
Corneel Coens et al.
LANCET ONCOLOGY (2020)
Artificial intelligence in cancer therapy
Dean Ho
SCIENCE (2020)
Characteristics and Outcome of AKT1E17K_Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
Methodology, results, and publication of oncology clinical trials: Insights from all the world’s randomized controlled trials (RCTs) 2014-2017.
Shubham Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multiplex digital spatial profiling of proteins and RNA in fixed tissue
Christopher R. Merritt et al.
NATURE BIOTECHNOLOGY (2020)
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Asaf Zviran et al.
NATURE MEDICINE (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Increasing operational and scientific efficiency in clinical trials
Deirdre Kelly et al.
BRITISH JOURNAL OF CANCER (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Behnam Nabet et al.
NATURE COMMUNICATIONS (2020)
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman et al.
NATURE CANCER (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
Mentorship in Medicine and Other Health Professions
Nayanee Henry-Noel et al.
JOURNAL OF CANCER EDUCATION (2019)
A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness
Michael Anderson et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Rapid research autopsy is a stealthy but growing contributor to cancer research
Eleonora Duregon et al.
CANCER (2019)
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
Cynthia Huang Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials
Derek Kyte et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Bishal Gyawali et al.
JAMA INTERNAL MEDICINE (2019)
Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports
Kenneth L. Kehl et al.
JAMA ONCOLOGY (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
A reality check of the accelerated approval of immune-checkpoint inhibitors
Jennifer Gill et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition
Derek C. Angus et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P. Hobbs et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study
Vineeta Agarwala et al.
HEALTH AFFAIRS (2018)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Roche pays $1.9 billion for Flatiron's army of electronic health record curators
Justin Petrone
NATURE BIOTECHNOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global Cancer Clinical Trials-Cooperation Between Investigators in High-Income Countries and Low- and Middle-Income Countries
Pankaj Kumar Panda et al.
JAMA ONCOLOGY (2018)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen et al.
NATURE (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Developing mentorship in a resource-limited context: a qualitative research study of the experiences and perceptions of the makerere university student and faculty mentorship programme
Andrew S. Ssemata et al.
BMC MEDICAL EDUCATION (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang et al.
ANNALS OF ONCOLOGY (2017)
Automated eligibility screening and monitoring for genotype-driven precision oncology trials
Michael H. Eubank et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2016)
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials
Joseph M. Unger et al.
JAMA ONCOLOGY (2016)
Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
Jan Bogaerts et al.
EUROPEAN JOURNAL OF CANCER (2015)
Clinical trial design for rare cancers: why a less conventional route may be required
Katherine S. Panageas
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2015)
Global migration of clinical trials
Paul K. Drain et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Research Participation by Low-Income and Racial/Ethnic Minority Groups: How Payment May Change the Balance
Jennifer K. Walter et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
Bryce B. Reeve et al.
QUALITY OF LIFE RESEARCH (2013)
Identifying Personal Genomes by Surname Inference
Melissa Gymrek et al.
SCIENCE (2013)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
Laura J. Esserman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
John R. Johnson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Speeding up the evaluation of new agents in cancer
Mahesh K. B. Parmar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Increasing minority participation in cancer clinical trials: The minority-based community clinical oncology program experience
W McCaskill-Stevens et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials
WB Sateren et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
